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Diabetic nephropathy is a severe complication and few
studies have described the early morphological changes over
time. Two kidney biopsies were performed, within a 6-year
interval, in 29 primarily normoalbuminuric patients, aged 24
years at the second biopsy. These were examined with light
and electron microscopy. Glomerular filtration rate, and
effective renal plasma flow were determined with inulin and
para-aminohippurate clearances. Urinary albumin excretion
rate and the 24 ambulatory blood pressure were determined.
Ten patients had developed microalbuminuria and/or
hypertension; of these, six were treated with
antihypertensive medication for 2 years or more. Significant
increases were found in night time diastolic blood pressure
and decreases in systolic and diastolic dipping. The
glomerular volume, mesangial volume, mesangial matrix
volume fraction and foot process width increased
significantly. The group that was treated later for
complications had the worst long-term metabolic control,
thicker basement membranes and larger mesangial matrix
and volume at the first biopsy, than the persistent
normoalbuminuric group. During the follow-up, the
untreated group with complications and the persistent
normoalbuminuric group showed an increase in
morphological parameters, whereas no progression occurred
in the treated patients who also improved their metabolic
control. In conclusion, the morphological parameters
deteriorated in the normoalbuminuric patients and in those
with complications, but were unchanged in the small
antihypertensive-treated group with improved metabolic
control.
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The well-known report by Kimmelstiel and Wilson in 1936
on glomerular changes in advanced diabetic nephropathy
(DN) was the first description of this pathological finding. In
the 1970s, Ruth Østerby described the earliest changes in the
glomeruli of diabetic patients, with thickening of the
basement membrane.1 During the past 30 years, more
morphological changes have been reported, including the
increase in the mesangial matrix and mesangial volume
fractions,2–7 which resulted in the concept of diabetic
glomerulopathy (DG). The patients with DG developing
microalbuminuria (MA) may change spontaneously,8 with
better metabolic control9,10 and/or the introduction of
antihypertensive treatment (AHT).11
Today, DN is the most prevalent disease in Sweden and the
Western world causing end-stage renal disease.12,13 The
mortality rate among patients with diabetes on renal
replacement therapy is high.12,13
In a group of normoalbuminuric (NA) and normotensive
(NT) adolescents, we studied the relationships between long-
term renal function, the ambulatory blood pressure (AMBP),
metabolic control and kidney morphology.6,14,15 The cohort
included 46 patients who have now been followed for about 6
years since the first biopsy; 29 have had a second biopsy. We
have previously reported the 19 patients who remained
normoalbuminuric and normotensive (called NANT) until
the second biopsy.16 The present report concerns the
morphological and clinical changes during a 6-year follow-
up period in the entire rebiopsied group.
RESULTS
Ten of the 29 (16 males) rebiopsied patients had developed
hypertension (HT) and/or MA and six of them were on AHT
for 2 years or more.
There was no significant difference in metabolic control in
the 29 patients, as determined by the mean yearly
hemoglobin A1c (HbA1c) and the actual HbA1c at the times
of the biopsies (Table 1) or urinary albumin excretion rate
(UAE) between the first and second biopsy (6 vs 5.5 mg/min).
The daytime blood pressure (BP) was unchanged, but
significant changes in the night time diastolic BP, systolic
and diastolic dipping occurred between the first and second
biopsies (Table 1).
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Changes in renal morphology in all rebiopsied patients
In the whole group of 29 patients, the GV in absolute terms
and in relation to BSA increased significantly between the
biopsies (Table 1, Figure 1a). The basement membrane
thickness (BMT) showed a tendency, although not signifi-
cant, to increase between the biopsies, but when related to
BSA, it did not change (Table 1, Figure 1b). The VV (matrix/
glom) (mesangial matrix volume fraction) and VV (mes/
glom) (mesangial volume fraction/glomerulus) increased
significantly from the first to the second biopsy (Table 1,
Figure 1c and d). We found significant increases in the foot
process width (Table 1, Figure 1e) while the total slit pore
length was unchanged (Table 1).
Renal function
No changes occurred in the glomerular filtration rate (GFR),
effective renal plasma flow (ERPF), and filtration fraction
(FF) from the first to the second biopsy (Table 1). Neither did
the mean previous GFR (137 (18) and 135 (17) ml min1 per
1.73 m2), the mean previous ERPF (637 (85) and 635
(94) ml min1 per 1.73 m2), or the mean previous FF (21.8
(3) and 21.7 (3)%) before the first and second biopsy,
respectively). GFR and FF were significantly higher than in
the controls matched for age and gender (GFR Po0.001 on
both occasions, FF Po0.0001 and 0.003). Their ERPF values
were similar on both biopsies and in the controls.
Thirteen patients on the first biopsy and 11 patients on
second biopsy were still hyperfiltrating, although some were
treated with AHT. No differences were noted in kidney
function between the normoalbuminuria (NA), AHT, and
MA/HT groups. The five ACE-inhibitor (ACE-I)-treated
patients showed a tendency to fall in GFR from mean
152 ml min1 per 1.73 m2 on the first biopsy to mean
Table 1 | Clinical and morphological data of the 29 type I diabetes patients who underwent two biopsies
First biopsy, N=29 Second biopsy, N=29 P-value
Age (years) 18.6 (15.2–19.3) 24.0 (20.9–26.5)
Duration (years) 10.7 (8–12.7) 17.2 (14.2–19.4)
Mean of all yearly HbA1c 7.9 (7.6–8.6) 8.0 (7.6–8.3) NS
HbA1c at biopsy 7.7 (6.9–8.2) 7.2 (6.7–8.1) NS
GFR (ml min1 per 1.73 m2) 134 (24) 132 (24) NS
ERPF (ml min1 per 1.73 m2) 622 (134) 649 (160) NS
FF (%) 22.0 (2.6) 21.0 (3.3) NS
Daytime systolic BP (mmHg) 129 (9) 126 (10) NS
Daytime diastolic BP (mmHg) 76 (73–79) 75 (71–79) NS
Night time systolic (mmHg) 112 (10) 113 (9) NS
Night time diastolic (mmHg) 58 (56–62) 62 (57–66) 0.023
% Systolic dipping 14 (9–15) 10 (8–12) 0.025
% Diastolic dipping 22 (19–28) 18 (12–23) 0.006
GV (Mmm3) 2.5 (2.2–3.1) 3.4 (3.0–3.8) 0.00005
GV (Mmm3 per 1.73 m2) 2.6 (2.2–3.0) 3.2 (2.8–3.7) 0.0005
BMT (nm) 481 (446–545) 515 (470–592) 0.059
BMT per 1.73 m2 (nm) 488 (448–563) 482 (446–522) NS
VV (matrix/glomerulus) (%) 10.6 (1.9) 11.9 (2.0) 0.014
VV (mes/glomerulus) (%) 19.5 (17.7–21.5) 23.0 (20.0–24.0) 0.00013
Foot process width (nm) 416 (392–455) 455 (419–484) 0.0007
Slit pore length density (mm2) 0.348 (0.06) 0.287 (0.06) 0.00001
Total slit pore length (m per 1.73 m2) 0.85 (0.75–1.09) 0.91 (0.74–1.07) NS
Results are given as mean (s.d.) or median (lower–upper quartiles). NS=not significant.
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First biopsy Six years later
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Figure 1 | (a–e) Glomerular volume (Mmm3 per 1.73 m2), basement
membrane thickness (nm per 1.73 m2), Vv (mesangial matrix volume
fraction/glom) (%), Vv (mesangial volume fraction/glom) (%), and foot
process width (nm) on the first and second biopsies. The gray dotted
lines represent the NANT patients (n¼ 19), the circles and thick lines
AHT-treated patients (n¼ 6). The open rectangles with the long
interrupted lines represent the patients who developed MA and/or
HT, but had not yet been treated (n¼ 4).
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137 ml min1 per 1.73 m2 on the second biopsy (P¼ 0.15).
The change in GFR between the biopsies was 15 ml min1
per 1.73 m2 in the ACE-I group vs þ 0.3 ml min1 per
1.73 m2 in the untreated group (P¼ 0.063). FF did not
change in untreated or ACE-I group.
We found positive correlations between the mean FF
before the first biopsy and the BMT, VV (matrix/glom) and
VV (mes/glom) on the first biopsy. However, on the second
biopsy, we did not find any correlations between kidney
function and the morphometric parameters or in the changes
in morphology between the biopsies.
Differences between the NA, AHT, and MA/HT groups
The AHT group had poorer metabolic control before the first
biopsy than the NANT group (Table 2). Unlike the latter
group, in whom the morphological parameters became more
severe, the AHT group showed no further deterioration in
morphology and a decrease in HbA1c (Table 2). Before the
first biopsy, the MA/HT group had the same level of HbA1c as
the NANT group, but between the biopsies, their metabolic
control became worse (Table 2).
No significant changes in AMBP occurred in the groups or
between the biopsies, but the MA/HT group showed less
systolic dipping than the AHT group. We found a decrease in
BMT between the biopies in the AHT group and a tendency
to an increase in the MA/HT group. On the first biopsy, the
VV (matrix/glom) and VV (mes/glom) were larger in the
AHT group and showed no change during the follow-up, but
in the NANT and MA/HT groups, they increased. GV and
foot process width increased significantly in the NANT
group, but did not change significantly in the AHT or MA/
HT group. The total slit pore length did, however, not differ
or change between the groups and biopsies.
Single regression analyses of morphology on the second
biopsy
Table 3 gives the correlations between the morphological
parameters on the second biopsy or the morphological
changes between the biopsies (D) and various clinical
parameters. We found that the long-term metabolic control
correlated strongly with BMT and also with VV (matrix/
glom), and VV (mes/glom) on the second biopsy. The
metabolic control between the biopsies correlated closely
with the DBMT, DVV (matrix/glom), and DVV (mes/glom).
No correlations were noted between duration, gender,
height, or any morphological parameters on the second
biopsy, but age and the postpubertal duration correlated with
the foot process width. Log UAE correlated most strongly
Table 2 | Comparisons between clinical and morphometric parameters in the groups of patients who, at the time of the second
biopsy, were still normoalbuminuric and normotensive (NANT) or had received antihypertensive treatment during the follow-
up because of MA or HT (AHT) or had developed complications, but had not yet been given AHT (MA/HT)
NANT AHT MA and/or HT
n=19, 1st
biopsy
n=19, 2nd
biopsy P-value
n=6, 1st
biopsy
n=6, 2nd
biopsy P-value
n=4, 1st
biopsy
n=4, 2nd
biopsy P-value
Duration a 10.6 17.2 12.1 19.1 9.7 15.0
HbA1c a 7.7 7.7 8.85 8.25 0.03 8.0 8.5 0.07
HbA1c between
biopsies
a 7.6 6.9 9.0
% syst dipping a 10.9 10.1 14.8 11.8 14 6.6
BMT (nm) a 480 471 585 510 0.046 497 524
Matrix/glom b 10.3 11.4 0.01 12.6 12.1 8.7 14 0.02
Mes/glom b 19.2 22.3 o0.001 22.2 23.7 17.0 25.6 0.02
Compari-
sons be-
tween the
groups at
1st biopsy
Compari-
sons be-
tween the
groups at
2nd biopsy
P-value
between
NANT and
AHT groups
at 1st
biopsy
P-value
between
NANT and
AHT groups
at 2nd
biopsy
P-value
between
NANT and
MA/
HTgroups
at 1st
biopsy
P-value
between
NANT and
MA/HT
groups at
2nd biopsy
P-value
between
AHT and
MA/HT
groups at
1st biopsy
P-value
between
AHT and
MA/HT
groups at
2nd biopsy
Duration
HbA1c 0.015 0.017 0.015 0.03
HbA1c between
biopsies
0.009 0.0069
% syst dipping 0.054 0.048
BMT (nm) 0.007 0.005
Matrix/glom 0.0045 0.002 0.0066
Mes/glom 0.014 0.015
Duration of diabetes is given in years. HbA1c is the mean of all yearly HbA1c until the first and second biopsy, respectively. HbA1c between biopsies refers to the mean of yearly
HbA1c between the biopsies. The BMT have been corrected for 1.73 m
2. The matrix/glom and mes/glom refers to the volume fraction of mesangial matrix in the glomerulus,
VV (matrix/glom), and the volume fraction of the mesangium in the glomerulus, VV (mes/glom), in %. Only significant changes are given.
a=median; b=mean.
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with VV (matrix/glom) but also with VV (mes/glom) and
inversely with slit pore length density (r2¼ 30%, P¼ 0.013),
but not with total slit pore length.
The daytime diastolic BP correlated directly with the BMT
and foot process width.
Multiple regression analyses of morphology on the second
biopsy
In the multiple regression analyses, the BMT and VV (matrix/
glom) on the second biopsy were ascribed to gender (males at
risk) and long-term metabolic control (adjusted r2¼ 64%,
Po0.0001 and adjusted r2¼ 24%, P¼ 0.01, respectively).
Furthermore, the long-term metabolic control and log UAE
explained 63% of the VV (matrix/glom) (Po0.0001).
DISCUSSION
Our aim in this study was to determine over time the changes
in kidney morphology in a cohort of normoalbuminuric,
NANT patients with type I diabetes.
One-third of these patients developed MA and/or HT after
having diabetes for 17 years, and the DG changes became
worse, although not all patients showed clinical signs of this.
Those who developed a complication and have been given
AHT and improved their metabolic control did not progress
in their morphological changes.
We corrected the GV and BMT for body surface area
(BSA) as we are studying growing adolescents and young
adults. The large GV agrees with the findings of others,5,17 as
also does the increase in GV between the biopsies.18,19 We
found increases in both the NANT group and the entire
group, although others report GV expansion only in MA
patients or in relation to UAE.3,5,7,20
In the present study, no significant change occurred in
BMT, when corrected for BSA in the whole group of patients,
a finding also reported by Fioretto,18 who studied NA and
MA patients as well. In our AHT-treated group, however, we
observed a decrease in BMT between the biopsies. In the
untreated NANT and MA/HT group, the VV (matrix/glom)
and VV (mes/glom) increased during the 6-year follow-up,
which have been reported in follow-up studies of NA and MA
patients.18,19,21 Our AHT-treated patients showed stable VV
(matrix/glom) and VV (mes/glom). In the ESPRIT study,
22 no
changes were seen in the AHT-treated (enalapril or
nifedipine) and placebo groups. In that study, all patients
were micro- or macroalbuminuric and had advanced
morphological changes, even at the start of treatment, which
may indicate irreversible morphological changes or too short
a treatment. Some believe that it may take as long for the
morphological changes to resolve as they did to develop.22
Fioretto showed a decrease in the morphological parameters
only after 10 years of normoglycemia following a pancreas
transplantation and, in the ESPRIT study, it was suggested
that 36 months of treatment was too short to change the
morphology.22,23 However, we found a regression or stable
morphological values after only 2 years of AHT treatment in
combination with improved metabolic control. This would
suggest that the very early DG changes are reversible. In an
antihypertensive study of MA patients, no change occurred in
BMT during 3 years, neither with ACE-I nor with
metoprolol.24 The authors suggest that a better metabolic
control in the metoprolol-treated group was the reason for
the lack of progression in that group.
The high correlations that we observed between morpho-
logy and long-term metabolic control and the correlation
Table 3 | Regression analyses of various morphological parameters on the second biopsy or changes between the biopsies (D
morphology), as dependent variables
Univariate regression analyses
Dependent variables
Independent variables DBMT BMT
DVV (matrix/
glom) VV (matrix/glom) DVV (mes/glom) VV (mes/glom)
Foot process
width
HbA1c until 2nd biopsy 51%, Po0.0001,
78 nm
23%, P=0.012,
1%b
27%, P=0.005,
1.6%a
NS
HbA1c between the
biopsies
50%, Po0.0001,
59 nm
42%, P=0.0002,
1.4%
45%, P=0.0001,
2.05%a
Age on 2nd biopsy NS NS NS 34%, P=0.0012,
7.4 nma
Postpubertal duration NS NS NS 28%, P=0.004,
6.3 nma
Log UAE (n=20) NS 66%, Po0.0001,
2.9%b
41%, P=0.002,
3.9%
NS (P=0.18)
Daytime diastolic BP 29%, P=0.003,
5.8 nmb
14%, P=0.049,
3.3 nm
Night time diastolic BP 14%, P=0.054,
4 nmb
NS=not significant.
Duration is the duration of diabetes since onset until examination, and age is given in years. HbA1c until 2nd biopsy is the mean of all yearly HbA1c until second biopsy. HbA1c
between the biopsies is the mean of yearly HbA1c between the biopsies. Postpubertal duration is the duration of diabetes after puberty. DBMT and BMT are corrected for (in
%) 1.73 m2. Results are given in the univariate regression analyses as R2, P-level and estimate. The estimate refers to the effect on the dependent variable if the independent
variable changes one unit (e.g. if HbA1c increases 1% the BMT will increase 78 nm).
aOne patient excluded because of high Cook’s distance.
bTwo patients excluded because of high Cook’s distance.
702 Kidney International (2006) 69, 699–705
o r i g i n a l a r t i c l e NESS Perrin et al.: Serial kidney biopsies in type I diabetes patients
between changes in morphology and metabolic control
between the biopsies accord with those of other stu-
dies19,21,25,26 and emphasize the importance of good meta-
bolic control. The unchanged DG parameters found in the
AHT group may have been either owing to the AHT or the
effect of the improvement in metabolic control. We think that
the information to the patients of the need of treatment
(AHT) for a complication is scaring and increase the patients’
awareness of the importance of a good metabolic control.
This may explain the improvement in metabolic control in
the AHT group.
The increase in foot process width that we found on
repeated biopsies have not been reported before so far as we
know. The total slit pore length, as a product of slit pore
length density and GV, was unchanged in contrast to a
decrease in the slit pore length density. The total slit pore
length is probably a more interesting factor to analyze,
reflecting the total filtration area. The glomerular expansion
between the biopsies is probably caused by compensatory
mechanisms or secondary to pubertal changes. Other authors
have shown a decrease in filtration surface area with
duration7 or between biopsies.18 Our first biopsy showed
an increase in foot process width and a decrease in the slit
pore length density with increasing UAE,6 which have also
been reported by others.27–29 In the present study, on the
second biopsy, we observed only an inverse correlation
between UAE and the slit pore length density, but not with
the total slit pore length.
The patients were still hyperfiltrating on the second
biopsy, as compared to the controls. The GFR showed no
change between the biopsies, as noted by others.18 We found
no correlation between the actual or long-term GFR and
morphology on the second biopsy or the morphological
changes between the biopsies. Other authors likewise have
detected no correlation between GFR and morpho-
logy.7,19,21,26,30 However, Mauer et al.,31 who studied patients
with severer morphological changes than our patients,
reported a decrease in GFR in patients with mesangial
expansion exceeding 30%. The ESPRIT study,22 which
included micro- and macroalbuminuric patients, also showed
a decline in GFR with time, age, and the severity of
albuminuria. Therefore, the change in GFR seems to occur
only after DG has deteriorated to DN with marked mesangial
expansion.7,31 The total slit pore length and the GFR were
unchanged. We found no correlation between GFR and the
total slit pore length, which may be caused by the short
duration of the disease, small changes in filtrations slits, and a
compensatory mechanism of the glomeruli to expand.
Another explanation may be that mesangial expansion in
an enlarging glomerulus, as we have shown, causes less
damage than if the glomerulus cannot dilate any more.32
Therefore, the GFR of our patients may change in future.
During the follow-up, our entire cohort showed an
increase in night time diastolic BP. On the first biopsy, our
group has reported a correlation between the night time BP
and BMT, VV (matrix/glom), and the foot process width.
14
Moreover, the night time BP on the first biopsy predicted
some morphological changes on the second biopsy in the NA
group.16 On the second biopsy, the daytime diastolic BP
correlated both to BMT and foot process width. Our group
has also shown that non-dippers (systolic dipping o7%,
diastolic dipping o14%) had severer morphological
changes,15 which accords to this study where we found less
dipping in the MA/HT group. In accordance with our results,
Drummond et al.7 noted a correlation between the daytime
diastolic BP and morphology. Thus, AMBP seems more
informative than casual BP to which other authors did not
find any correlations to morphology.3,5,19,21,25,28,33
In conclusion, the DG changes increased in NA patients
and MA/HT group. However, the small group with better
metabolic control and on AHT treatment showed no further
advance of the DG, which indicates the importance of good
metabolic control and strict BP surveillance and perhaps
AHT early in the diabetic course.
MATERIALS AND METHODS
Patients
All patients with type I diabetes over 12 years of age, who had had
diabetes for more than 5 years and attended the Children’s Hospital
at Karolinska University Hospital, Huddinge, were asked at the
beginning of 1992 to take part in a kidney biopsy study in
connection with their regular kidney function investigation. Forty-
six unselected normoalbuminuric and normotensive patients had
the first kidney biopsy carried out between 1992 and 1994,
at a median age of 18 years. Six years later, they were asked
to undergo a second kidney biopsy, 29 patients agreed and 17
declined. There were no differences in the clinical findings, renal
function, or morphological parameters on the first biopsy in the
patients, who underwent a second biopsy, as compared with those
who did not.
Of the 29 patients, aged 24 (21–26) years, who had had a second
biopsy 17 (14–19) years after the onset of diabetes, 19 were still
normoalbuminuric and normotensive,16 but 10 had developed HT (8
patients) and/or MA (4 patients). Seven patients had been treated
during some part of this period, but one for less than a year and he is
therefore regarded as an untreated patient with complications. Five of
the treated patients received ACE-inhibitors because of MA (two
patients) and HT (three patients) and one a b-blocker because of HT.
At the time of the second biopsy, they were classified as patients
who (a) were normoalbuminuric and normotensive (called NANT),
(b) developed complications and were on AHT during at least 2 years,
or (c) developed MA and/or HT during the follow-up, but had not
started treatment at the time of the second biopsy (MA/HT).
The investigations were performed over a 3-day period as
described in the previous paper.16
The study was approved by the Ethics Committee of Karolinska
Institutet and carried out after informed consent had been obtained
from the patients.
Clinical follow-up
After the first biopsy, patients were examined clinically every third
month in the Children’s Hospital or, after the age of 18–20 years, in
the Adult Diabetic Out-patient Clinic at Karolinska University
Hospital, Huddinge. At every check-up, the HbA1c and BP were
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measured, and at least once or twice yearly, the UAE. The diagnosis
of HT was made either by casual measurements or via AMBP
measurements. The patients who had casual HT (4140/
80–90 mmHg) on several occasions were classified as hypertensive.
If they had a single measurement of casual HT, they underwent
AMBP. If mean daytime or night time systolic and/or diastolic
BP495th percentile for a given height and gender,34 he was classified
as hypertensive. Eight patients were classified as hypertensive.
Four patients developed persistent MA, defined as UAE
420 mg min1 in two of three urine samples during a 6-month
period.
Metabolic control
Metabolic control was evaluated every third month as HbA1 or
HbA1c. The HbA1 values were converted to HbA1c.
16 The normal
reference values of HbA1c are 3.4–5.0%, which are about 0.7–1.0%
lower than those in the Diabetes Control and Complication
Trial study.35,36 The long-term metabolic control was determined
by the mean of all yearly HbA1c.
16 The metabolic control between
the biopsies was calculated as the mean of yearly HbA1c between the
first and second biopsy.
Ambulatory BP
The 24-h AMBP was recorded with portable automatic Space Labs
90 207 equipment (Space Labs Inc., Wokingham, UK), as described
elsewhere.14,15,34 AMBP readings were successful in a median of 90%
at the first biopsy and 94% at the second biopsy.
No AMBP was carried out in two patients at the first biopsy. The
percentage of the night time fall in BP (‘dipping’) was calculated as:
(daytime BPnight time BP) 100/daytime BP.37,38 Soergel et al.38
found 13 (6)% systolic and 23 (9)% diastolic dipping in controls.
Urine samples
UAE was determined in timed overnight urine collections with an
automated immunonephelometric method (Behring Nephelometer
Analyser; Behringwerken, Marburg, Germany) on the first biopsy,
and an immunoturbidometric method (Roche Regencies and
Hitachi equipment 917; Roche, Boston, MA) during the follow-up
and on the second biopsy. Both methods were calibrated to show the
same values. The detection limit for the albumin concentration was
4 mg l1.
On the first biopsy, no urine samples were available in four
patients and six had urinary albumin concentrations below the
detection level; on the second biopsy, 10 patients had values below
the detection level.
Puberty status
The median age at the onset of diabetes was 7.2 (3.7–10.5) years
and all our patients were regarded as having had their onset
before puberty. As accurate data based on Tanner’s values
were not available in all cases, we arbitrarily chose the age of 11
years in female and of 12 years in male patients for the start of
puberty.39,40
Renal function tests
Renal function was determined every second or third year from the
onset of diabetes and mean 3.5 and 5.5 renal function tests were
performed before first and second biopsy, respectively. The means of
all previous renal hemodynamic data were calculated for each
patient before the first and second biopsy.
GFR and ERPF were determined by clearances of inulin and
para-aminohippuric acid as described previously.16 In the statistical
analyses, various measurements of GFR have been used, for
example, the GFR at the first and second biopsy, the difference
between the GFR at the biopsies and the mean of previous GFR
before the first and second biopsy. We compared the patients’ renal
function with that of 58 healthy children and young adults
(presumptive kidney donors), who had been matched for age and
gender, evaluated in our unit. The controls had GFR 116
(11) ml min1 per 1.73 m2 and 115 (13) ml min1 per 1.73 m2,
ERPF 640 (99) ml min1 per 1.73 m2 and 628 (113) ml min1 per
1.73 m2, and FF 18.4 (2.5)% and 18.7 (2.8)% at ages corresponding
to first and second biopsy (median 18.5 and 24.0 years of age,
respectively). Hyperfiltration was defined as a GFR42 s.d. of the
controls.
Renal biopsy
The biopsies were taken under local anesthesia with ultrasound
guidance (Acuson XP 10 and Acuson Sequoia 512, Mountain View,
CA), an automatic biopsy device (Bard Magnum Biopsy Instrument;
Urological, Covington, CA) and a 16-G needle (Bard Magnum Core
Tissue Biopsy Needle; Urological) as described in the previous
paper.16 Samples for light and electron microscopy were postfixed in
2% glutaraldehyde and 4% paraformaldehyde in phosphate buffer
and embedded in Polybed 812.16 Every biopsy was examined by a
single nephropathologist (GAJ) without the knowledge of the
patient’s history.
The morphometric analyses in the light and electron microscopy
(Philips 420, Eindhoven, The Netherlands) were carried out in the
same way as described previously.16 The sampling of the glomerular
profiles taken for ultra-thin sectioning was carried out and corrected
by a grating grid (EF Fullan Inc.; 28 800 lines inch1), as described
elsewhere.6 In the grid, the surface density of the peripheral capillary
walls, SV (pcap/glom), was calculated using the intersections (I) with
the formula:
SV ðpcap=glomÞ ¼ 2I=ðPð2d=magÞÞ ðmm1Þ
and the length density of filtration slits (LV (slit pore/glom)) using
the number of their related filtration slits (Q) was estimated with the
formula:
LV ðslit pore=glomÞ ¼ 2Q=ðPðd2=mag2ÞÞ ðmm2Þ
In the formulas above, P is the total points in the reference space,
d is the distance between each point of the grid and mag is the final
magnification.
The total slit pore length per mean glomerular volume (GV) (m)
was estimated by multiplying mean GV (Mmm3) and the slit pore
length density (LV (slit pore/glom) (mm
2).
We analyzed the absolute values of GV and BMT and the 1.73 m2
BSA-corrected values, as we were studying growing adolescents. In
Table 1 and in the first paragraph on changes in renal morphology,
we report the corrected and uncorrected values, but in the following
text and in Tables 2 and 3, the GV and BMT values have been
corrected for BSA.
Statistical analyses
The mean and s.d. are given for normally distributed values and
median and lower and upper quartiles for skewed data. The
Student’s paired t-test was used for normally distributed variables.
The Mann–Whitney U-test and Wilcoxon’s matched-pair test were
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used for continuous data not normally distributed. When compar-
ing the groups, one-way analysis of variance (ANOVA) was used,
followed by post hoc t-tests with the Bonferroni adjustment. For
variables having a skewed distribution, we used Kruskal–Wallis
ANOVA by ranks, with Bonferroni adjustment.
Univariate and multiple regression analyses were employed to
evaluate the correlations between the clinical and morphological
findings. Values were excluded if the analyses of residuals and Cook’s
distance showed an outlier. Not more than two factors entered in the
multiple regression analyses owing to the small sample size. Po0.05
was considered significant, but in the multiple regression analyses, a
P-value o0.01 was considered significant in order to approximately
maintain an overall 5% level. The statistical program of Statistica 6.1
was used.
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